A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination with Durvalumab in Selected Advanced Solid Tumors

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/16/MH/424
NMA SSA Reference Number: SSA/18/MonH/393
Monash Health Ref: RES-18-0000261X
Effective start/end date25/03/198/10/20


  • clinical trial
  • advanced solid tumor
  • phase 1 study
  • treatment efficacy